rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Sireesh Appajosyula

Chief Operating Officer

Company insider

Files Form 4 as: Chief Operating Officer, Hepion Pharmaceuticals; CEO, Canton Strategic Holdings.

In numbers

Trades disclosed
21
Buys
6
Sells
0
Bought
$420K
Sold
$0
Companies
2
Companies where not an officer
0
First trade
21 Mar 2022
Last trade
19 Aug 2026
Last filed
21 Aug 2026

Companies traded

Where they are an officer
Hepion PharmaceuticalsDirector, Officer · Biotechnology · last 19 Aug 20262 buys · 0 sells
CNTN Canton Strategic HoldingsDirector, Officer · Digital Asset Treasuries · last 3 Nov 20254 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
19 Aug 2026filed 21 Aug 2026Hepion Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—1,345,500 at $0.00filing
19 Aug 2026filed 21 Aug 2026Hepion Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—1,345,500 at $0.00filing
3 Aug 2026filed 12 Aug 2026Hepion PharmaceuticalsBiotechnologySEC FORM 4 Bought$100K2,000,000 at $0.05filing
3 Aug 2026filed 12 Aug 2026Hepion Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code P—2,000,000 at $0.00filing
3 Aug 2026filed 12 Aug 2026Hepion Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code P—2,000,000 at $0.00filing
3 Aug 2026filed 12 Aug 2026Hepion PharmaceuticalsBiotechnologySEC FORM 4 Bought$100K2,000,000 at $0.05filing
21 Apr 2026filed 27 Apr 2026Hepion PharmaceuticalsBiotechnologySEC FORM 4 Bought$50K1,250,000 at $0.04filing
21 Apr 2026filed 27 Apr 2026Hepion PharmaceuticalsBiotechnologySEC FORM 4 Bought$50K1,250,000 at $0.04filing
3 Nov 2025filed 5 Nov 2025CNTN Canton Strategic Holdingsoption or derivative · Digital Asset TreasuriesSEC FORM 4 Code A—20,000 at $0.00filing
4 Aug 2025filed 6 Aug 2025CNTN Canton Strategic Holdingsoption or derivative · Digital Asset TreasuriesSEC FORM 4 Code A—90,000 at $0.00filing
20 Jun 2025filed 23 Jun 2025CNTN Canton Strategic HoldingsDigital Asset TreasuriesSEC FORM 4 Bought$90K60,806 at $1.48filing
20 Jun 2025filed 23 Jun 2025CNTN Canton Strategic HoldingsDigital Asset TreasuriesSEC FORM 4 Bought$980690 at $1.42filing
13 Jan 2025filed 14 Jan 2025CNTN Canton Strategic Holdingsoption or derivative · Digital Asset TreasuriesSEC FORM 4 Code A—52,875 at $0.00filing
13 Nov 2024filed 13 Nov 2024CNTN Canton Strategic HoldingsDigital Asset TreasuriesSEC FORM 4 Bought$10K5,000 at $2.02filing
8 Oct 2024filed 9 Oct 2024CNTN Canton Strategic HoldingsDigital Asset TreasuriesSEC FORM 4 Bought$9,6505,000 at $1.93filing
8 Oct 2024filed 8 Oct 2024CNTN Canton Strategic HoldingsDigital Asset TreasuriesSEC FORM 4 Bought$9,6505,000 at $1.93filing
9 Aug 2024filed 12 Aug 2024CNTN Canton Strategic Holdingsoption or derivative · Digital Asset TreasuriesSEC FORM 4 Code A—38,087 at $0.00filing
7 Nov 2023filed 9 Nov 2023CNTN Canton Strategic Holdingsoption or derivative · Digital Asset TreasuriesSEC FORM 4 Code A—25,000 at $0.00filing
14 Jul 2022filed 18 Jul 2022CNTN Canton Strategic HoldingsDigital Asset TreasuriesSEC FORM 4 Code G—75,757 at $0.00filing
14 Jul 2022filed 18 Jul 2022CNTN Canton Strategic HoldingsDigital Asset TreasuriesSEC FORM 4 Code G—7,576 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Digital Assets4
Health Care2

Buys in green, sells in red, by the company’s sector.

Related people

Danina FisherDirector · Director at Hepion Pharmaceuticals, filing Form 4 there in the last year
Vincent S. LoPrioreExecutive Chairman · Executive Chairman at Hepion Pharmaceuticals, filing Form 4 there in the last year
Michael J. PurcellDirector · Director at Hepion Pharmaceuticals, filing Form 4 there in the last year
Gary S. StetzInterim CEO · Interim CEO at Hepion Pharmaceuticals, filing Form 4 there in the last year
James Gordon LiddyDirector · Director at Hepion Pharmaceuticals, filing Form 4 there in the last year